J.P. Morgan has been appointed depositary bank by China Nuokang Bio-Pharmaceutical Inc. (‘Nuokang’) in connection with Nuokang’s recent initial public offering of 5,000,000 American Depositary Shares.
Nuokang is a leading bio-pharmaceutical company in China, focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. The company provides a diversified portfolio of products to more than 2,400 hospitals in China.
“Throughout the entire IPO process, J.P. Morgan’s depositary receipts team was extremely responsive to our needs. We look forward to partnering with J.P. Morgan to further develop our ADR program and to support our business expansion going forward,” says Xue Baizhong, chairman and chief executive officer of China Nuokang Bio-Pharmaceutical.
“We are pleased to be appointed depositary bank by Nuokang. We believe that our extensive experience in helping China-based companies enter the U.S. market will be instrumental in the continued success of Nuokang’s ADR program,” says Kenneth Tse, Asia Pacific head of J.P. Morgan’s depositary receipts group.
D.C.